BridgeBio Oncology
BBOT
34 hedge funds and large institutions have $178M invested in BridgeBio Oncology in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
10% more funds holding
Funds holding: 31 → 34 (+3)
1.22% more ownership
Funds ownership: 87.19% → 88.41% (+1.2%)
5% less capital invested
Capital invested by funds: $186M → $178M (-$8.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$4.81M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$3.31M |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$3.16M |
| 4 |
CS
Clear Street
New York
|
+$2.22M |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$4.5M |
| 2 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
-$4.23M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.72M |
| 4 |
Millennium Management
New York
|
-$2.15M |
| 5 |
Two Sigma Investments
New York
|
-$2.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Hudson Bay Capital Management
Stamford,
Connecticut
| $1.15M | +$1.17M | +108,300 | New |
|
|
WP
27
Woodline Partners
San Francisco,
California
| $1.1M | – | – | – |
|
|
MCM
28
Moore Capital Management
New York
| $1.06M | – | – | – |
|
|
KPF
29
K2 Principal Fund
Toronto,
Ontario, Canada
| $1.06M | – | – | – |
|
30
UBS Group
Zurich,
Switzerland
| $728K | -$261K | -24,126 | -26% |
|
|
GPP
31
Great Point Partners
Greenwich,
Connecticut
| $312K | -$3.72M | -344,452 | -92% |
|
|
FIA
32
FNY Investment Advisers
New York
| $289K | +$294K | +27,184 | New |
|
33
Geode Capital Management
Boston,
Massachusetts
| $142K | +$584 | +54 | +0.4% |
|
|
FLC
34
Fifth Lane Capital
Austin,
Texas
| $112K | +$113K | +10,500 | New |
|
|
35
T. Rowe Price Investment Management
Baltimore,
Maryland
| – | -$4.5M | -397,962 | Closed |
|
|
FBCM
36
Fort Baker Capital Management
Larkspur,
California
| – | -$4.23M | -374,683 | Closed |
|
|
37
Two Sigma Investments
New York
| – | -$2.14M | -189,285 | Closed |
|
|
SFM
38
Soros Fund Management
New York
| – | -$1.7M | -150,000 | Closed |
|
BBOT Hedge Fund Activity: Q2 2025 in Review
34 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q2 2025, worth a combined $178M — down 4.7% from $186M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BBOT positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was W.R. Berkley Corp, opening a new position worth an estimated $4.81M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $4.5M sold.
- 34 institutional investors held BridgeBio Oncology (BBOT) as of Q2 2025, up from 31 in Q1 2025.
- Funds reported $178M of BridgeBio Oncology stock for Q2 2025, down 4.7% quarter-over-quarter.
- 7 funds opened new BridgeBio Oncology positions in Q2 2025 and 4 closed out, a net change of +3 holders.
- The largest BridgeBio Oncology buyer in Q2 2025 was W.R. Berkley Corp, an estimated $4.81M added.
- The largest BridgeBio Oncology seller in Q2 2025 was T. Rowe Price Investment Management, an estimated $4.5M sold.
Based on aggregated 13F filings for Q2 2025.